Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: The Hoorn Study

Diabetic Medicine

Volumn 24, Issue 4, 2007, Pages 430-435

  Schindhelm, R K ^a   Dekker, J M ^a   Nijpels, G ^a   Stehouwer, C D A ^b   Bouter, L M ^a   Heine, R J ^a   Diamant, M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alanine aminotransferase; Elderly; Epidemiology; Metabolic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUCOSE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; CAUCASIAN; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GROUPS BY AGE; HEALTH PROGRAM; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX RATIO;

ADIPOSE TISSUE; AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; EPIDEMIOLOGIC STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 33947366047     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02100.x     Document Type: Article

References (28)

1. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419.
2. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003; 26: 3153-3159.
3. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666-673.
4. Meltzer AA, Everhart JE. Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol 1997; 146: 565-571.
5. Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005; 28: 1757-1762.
6. Schindhelm RK, Diamant M, Bakker SJL, van Dijk RA, Scheffer PG, Teerlink T et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest 2005; 35: 369-374.
7. Salvaggio A, Periti M, Miano L, Tavanelli M, Marzorati D. Body mass index and liver enzyme activity in serum. Clin Chem 1991; 37: 720-723.
8. Nakanishi N, Suzuki K, Tatara K. Serum γ-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004; 27: 1427-1432.
9. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005; 54: 3140-3147.
10. Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T et al. Chronological development of elevated aminotransferases in a non-alcoholic population. Hepatology 2005; 41: 64-71.
11. Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ et al. Prevalence and determinants of glucose intolerance in a Dutch Caucasian population. The Hoorn Study. Diabetes Care 1995; 18: 1270-1273.
12. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD et al. Relation of impaired fasting and post-load glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. J Am Med Assoc 2001; 285: 2109-2113.
13. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497.
14. Bergmeyer HU, Horder M, Rej R. International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2). J Clin Chem Clin Biochem 1986; 24: 481-495.
15. Grootenhuis PA, Westenbrink S, Sie CM, de Neeling JN, Kok FJ, Bouter LM. A semiquantitative food frequency questionnaire for use in epidemiologic research among the elderly: validation by comparison with dietary history. J Clin Epidemiol 1995; 48: 859-868.
16. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM et al. Intra-individual variation of glucose, specific insulin and pro-insulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996; 39: 298-305.
17. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 2016-2021.
18. Laaksonen DE, Lakka HM, Salonen JT, Niskanen LK, Rauramaa R, Lakka TA. Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. Diabetes Care 2002; 25: 1612-1618.
19. Palaniappan L, Carnethon MR, Wang Y, Hanley AJ, Fortmann SP, Haffner SM et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27: 788-793.
20. Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, Hakkinen AM et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004; 47: 1360-1369.
21. Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D, Sokolovskaya N et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. Quart J Med 1999; 92: 73-79.
22. Garg A, Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. J Clin Endocrinol Metab 2002; 87: 3019-3022.
23. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 1889-1895.
24. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-642.
25. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-3028.
26. Noto H, Raskin P. Hepatitis C infection and diabetes. J Diabetes Complications 2006; 20: 113-120.
27. Bruce MG, Bruden D, McMahon BJ, Christensen C, Homan C, Sullivan D et al. Hepatitis C infection in Alaska Natives with persistently normal, persistently elevated or fluctuating alanine aminotransferase levels. Liver Int 2006; 26: 643-649.
28. Veldhuizen IK, Conyn-van Spaendonck MA, Dorigo-Zetsma JW. Seroprevalentie van hepatitis B en C in de Nederlandse bevolking (Seroprevalence of hepatitis B and C in the Dutch population). Infectieziektenbulletin 1999; 10: 182-184.